Frankfurt - Delayed Quote EUR

MorphoSys AG (MOR.F)

67.60

-0.05

(-0.07%)

At close: April 26 at 8:00 AM GMT+2

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety ...

ACCESSWIRE 2 days ago

MOR

MPSYF
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Zacks 14 days ago

NVS

ARVN

MOR.DE
+0.15%
Novartis (NVS) to Undertake Job Cuts in Development Department

Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.

Zacks 15 days ago

NVS

MOR.DE
+0.15%
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, ...

ACCESSWIRE 15 days ago

MOR

MPSYF
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys

Novartis said on Thursday it has launched a tender offer to acquire MorphoSys , a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). Reuters reported in February that Swiss drugmaker Novartis would buy MorphoSys, which had an equity market value of around 1.6 billion euros before the offer was announced. The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected closing price on Jan. 25.

Reuters 15 days ago

NVS

MOR.DE
+0.15%
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with ...

ACCESSWIRE last month

MOR

MPSYF
MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript

MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript March 14, 2024 MorphoSys AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen. Welcome and thank you for joining MorphoSys Full Year 2023 Results and Business Update […]

Insider Monkey last month

MOR.DE
+0.15%
NVS
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.

Business Wire last month

MOR

MPSYF
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Zacks last month

EXEL

MOR.DE
+0.15%
LEGN
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Zacks last month

LEGN

EXAS

MOR.DE
+0.15%
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management ...

ACCESSWIRE last month

MOR

MPSYF
MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks last month

MOR.DE
+0.15%
What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 2 months ago

MPSYF
Q4 2023 Incyte Corp Earnings Call

Q4 2023 Incyte Corp Earnings Call

Thomson Reuters StreetEvents 2 months ago

INCY

MOR.DE
+0.15%
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.

Zacks 2 months ago

AMGN

CELG-RT

GILD
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Zacks 2 months ago

NVS

MOR.DE
+0.15%
INCY
MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte

The deals would hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.

BioPharma Dive 2 months ago

MOR.DE
+0.15%
NVS

INCY
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Investor's Business Daily 2 months ago

MOR.DE
+0.15%
NVS

INCY
UPDATE 3-Novartis to acquire cancer-focused MorphoSys for $2.9 bln

Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment candidate to its portfolio. Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%. The Swiss group will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances, the companies said.

Reuters 2 months ago

MOR.DE
+0.15%
NVS
Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H

Novartis has agreed to buy cancer specialist MorphoSys for €2.7 billion , with the deal expected to close in the first half of 2024.

The Wall Street Journal 2 months ago

CYTK

MOR

MPSYF

Performance Overview

Return	MOR.F	DAX PERFORMANCE-INDEX
YTD	+93.70%	+8.41%
1-Year	+258.15%	+14.42%
3-Year	-10.89%	+18.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MorphoSys AG (MOR.F)

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis (NVS) to Undertake Job Cuts in Development Department

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?

What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?

Q4 2023 Incyte Corp Earnings Call

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

UPDATE 3-Novartis to acquire cancer-focused MorphoSys for $2.9 bln

Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H

Performance Overview